Chanakya

Login

Jainee’s Coffee-Can Portfolio

jainee's Coffee Can portfolio
Updated: 5.30 PM, 17 April 2026
Jainee’s Coffee-Can Portfolio focuses on companies that combine clean balance sheets, consistent long-term growth, durable moats and stable cash flows. This week, our screening model has shortlisted stocks that deliver high-quality compounding, backed by 5–10 year stable earnings, strong capital efficiency, and leadership in their respective segments. Each company is evaluated on growth track record, profitability, valuation comfort, volumes, momentum indicators and longevity—ensuring only the most reliable wealth creators enter this portfolio.

Jainee’s Coffee Can Portfolio – 17 July 2026

(New Call every Week)

Divi’s Laboratories Coffee Can Analysis: India’s Global API Champion with Long-Term Pharma Leadership

Published: 17 July 2026

Introduction

Divi’s Laboratories Limited is one of India’s largest and most respected pharmaceutical companies, specialising in Active Pharmaceutical Ingredients (APIs), custom synthesis, intermediates and nutraceutical ingredients. Since its incorporation in 1990, the company has built a strong global reputation for manufacturing excellence, regulatory compliance and long-term partnerships with leading multinational pharmaceutical companies.

Today, Divi’s serves customers in over 100 countries and is among the world’s largest manufacturers for several generic APIs. Its business model combines high-volume generic APIs with high-margin custom synthesis contracts for global innovators, creating a diversified revenue stream with strong visibility.

The company operates three state-of-the-art manufacturing facilities located at Choutuppal, Visakhapatnam and Kakinada, supported by three advanced R&D centres employing nearly 700 scientists. Long-standing relationships with 12 of the world’s top 20 pharmaceutical companies further strengthen its competitive position and create high entry barriers.

With rising global outsourcing of pharmaceutical manufacturing, increasing demand for high-quality APIs, expanding nutraceutical consumption and India’s emergence as a preferred alternative to China in pharmaceutical supply chains, Divi’s Laboratories remains well positioned to deliver sustainable long-term growth.

For Coffee Can investors, Divi’s represents a rare combination of business quality, global leadership, healthy capital efficiency and consistent cash generation.

Coffee Can Matrix – Divi’s Laboratories

Parameter Data / Interpretation
CMP (Rs.) 7,247.50
P/E Ratio 73.31 → Premium valuation reflecting superior business quality and long-term earnings visibility.
Quarterly Net Profit (Rs. Cr.) 751.00
Quarterly Profit Growth (%) 13.44% → Healthy double-digit earnings growth despite a high base.
Quarterly Sales (Rs. Cr.) 2,831.00
Quarterly Sales Growth (%) 9.52% → Stable revenue growth driven by APIs and custom synthesis.
Sales CAGR (5 Years) 8.67% → Consistent long-term business expansion.
Profit CAGR (5 Years) 5.71% → Steady profit compounding reflecting disciplined execution.
All-Time High (Rs.) 7,390.00 → Trading only about 2% below its lifetime high, indicating strong investor confidence.
RSI 69.61 → Positive momentum, approaching the overbought zone.
1-Week Return 6.02% → Strong buying interest during the past week.
MACD 144.87
Previous MACD 132.60 → Momentum continues to strengthen with improving trend confirmation.
ROCE (%) 21.97% → Excellent capital efficiency, among the best in the Indian pharmaceutical industry.
Volume Trend 1 Day: 4.98 lakh vs 1-Month Avg: 4.54 lakh → Above-average trading activity indicates continued institutional participation.

Coffee Can Verdict – Divi’s Laboratories

👍 Positives (Coffee Can Strengths) ⚠️ Risks / Watchpoints
Global leader in Active Pharmaceutical Ingredients (APIs) Premium valuation leaves limited room for earnings disappointment
Long-term partnerships with 12 of the world’s top 20 pharma companies Revenue concentration in select high-value molecules
Among the world’s largest manufacturers for several generic APIs USFDA and global regulatory compliance remain critical
Diversified revenue from APIs, custom synthesis and nutraceuticals Currency fluctuations can impact export earnings
Strong manufacturing infrastructure with three world-class plants Global pricing pressure in generic APIs may affect margins
Nearly 700 scientists supporting continuous innovation and product development Capital-intensive expansion requires sustained execution
Excellent ROCE of nearly 22% reflecting efficient capital allocation Short-term profit booking possible as the stock trades near its lifetime high
Positive technical setup with improving MACD and above-average volumes RSI near 70 indicates limited near-term upside without consolidation

Final Verdict

Divi’s Laboratories has evolved into one of India’s highest-quality pharmaceutical businesses through decades of manufacturing excellence, scientific innovation and disciplined execution. Unlike many pharmaceutical companies that depend heavily on finished formulations, Divi’s has established a global leadership position in APIs and custom synthesis, creating a durable competitive advantage supported by scale, technology and stringent quality standards.

The company’s financial performance remains consistently strong. Quarterly profit grew over 13% while revenue increased nearly 10%, reflecting healthy demand despite a challenging global pharmaceutical environment. Five-year sales and profit growth further demonstrate the company’s ability to compound earnings over long periods without sacrificing operational efficiency.

A major strength of Divi’s lies in its long-standing relationships with leading multinational pharmaceutical companies. These partnerships generate recurring business, provide earnings visibility and create significant barriers for competitors. Simultaneously, the company’s expanding nutraceutical business offers an additional long-term growth avenue beyond traditional APIs.

From a valuation perspective, the stock trades at around 73 times earnings, one of the highest valuations in the Indian pharmaceutical sector. While this premium reflects exceptional business quality, global leadership and superior return ratios, it also means investors should avoid chasing sharp rallies and instead accumulate gradually during market corrections.

Technically, the stock continues to exhibit strong momentum. RSI stands at 69.61, indicating sustained buying interest but also suggesting that the stock is nearing the overbought zone. MACD continues to strengthen, volumes remain above average and the stock is trading just below its all-time high, reflecting strong institutional confidence.

Chanakya Coffee Can View

Divi’s Laboratories represents one of India’s finest pharmaceutical franchises, combining global API leadership, strong customer relationships, exceptional capital efficiency and robust cash generation. Its high-quality business model, manufacturing scale, research capabilities and structural growth opportunities make it an ideal Coffee Can stock for long-term investors seeking sustainable wealth creation. Although valuations are demanding, the company’s consistent execution and global competitive advantage justify a premium over most peers.

Preferred Strategy

Accumulate gradually during broader market corrections or temporary weakness rather than chasing the stock near its all-time high. Long-term investors may consider staggered buying to benefit from any valuation-driven pullbacks while participating in the company’s structural growth story.

For long-term study only. Not a buy/sell recommendation.

Start Your Trading Day with Chanakya Market Dashboard

Instead of visiting multiple market pages, begin your day with the Chanakya Market Dashboard, which brings together all key market insights in one place.

Related Market Insights 

1. Coffee Can Portfolio of 15 December 2025
 
 
 
 
 
 
 
 
 
10. Coffee Can Portfolio of 9 March 2026
 
11. Coffee Can Portfolio of 16 March 2026
 
 
 
 
 
 
 
 
 
 
 
 
 
What is Coffee Can Approach to Portfolio?

A coffee can portfolio is a long-term, low-risk investment strategy that involves buying shares of high-quality companies and holding them for a decade or more without active trading. The “buy and forget” method aims to capture long-term compounding by minimizing transaction costs and avoiding emotional decisions based on short-term market volatility. The name comes from an old-time practice of storing valuables in a coffee can. 
 
Key characteristics-
Long-term commitment: The core principle is to buy and hold for at least 10 years, allowing investments to grow over time.
Focus on quality: It emphasizes selecting companies with a proven track record of consistent performance, sound financials, and competitive advantages.
Minimal intervention: The strategy discourages frequent buying and selling, often referred to as the “buy and forget” method.
Reduces costs and stress: By limiting trades, it lowers transaction costs and reduces the stress of constantly monitoring the market.

Who is Jainee Shah/ Jainee P. Gordhandas?

Jainee P. Gordhandas (now Jainee Shah after marriage) is a Chartered Accountant and among the first SEBI-registered Research Analysts in India. Her analytical work and market insights are regularly published in the widely followed investment publications Chanakya Ni Pothi Gujarati and Chanakya Ni Pothi English.
Known for her sharp understanding of equity markets, she frequently appears on leading business television channels such as Gujarat Samachar TV, CNBC Gujarati, V TV, and others, where she discusses market trends, investment opportunities, and sectoral outlooks.
Her credibility, deep research skills, and years of market experience have made her one of the respected voices in the Indian investment community.

Jainee’s Coffee-Can Portfolio – Stocks Built for 5–10 Year Wealth Creation

Coffee Can Investing

Coffee Can Portfolio

Quicklinks

One thought on “Jainee’s Coffee-Can Portfolio”

Comments are closed.